Low efficacy of 18F-FDG PET for detection of uveal malignant melanoma compared with 123I-IMP SPECT

Journal of Nuclear Medicine

Volumn 47, Issue 3, 2006, Pages 404-409

  Kato, Katsuhiko ^a   Kubota, Toshinobu ^b   Ikeda, Mitsuru ^c   Tadokoro, Masanori ^d   Abe, Shinji ^e   Nakano, Satoshi ^e   Nishino, Masanari ^e   Kobayashi, Hidetoshi ^f   Ishigaki, Takeo ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d TOYOTA MEMORIAL HOSPITAL   (Japan)

^e NAGOYA UNIVERSITY HOSPITAL   (Japan)

^f FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

123I IMP SPECT; 18F FDG PET; Uveal malignant melanoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOFETAMINE I 123; DIAGNOSTIC AGENT; IOFETAMINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHOROIDAL HEMANGIOMA; CHOROIDAL NEVUS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG UPTAKE; FALSE NEGATIVE RESULT; FEMALE; HEMANGIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; NEVUS; PIGMENT EPITHELIUM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VOLUME; UVEA MELANOMA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; MELANOMA; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; UVEA TUMOR;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IOFETAMINE; MALE; MELANOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; UVEAL NEOPLASMS;

EID: 33645976921     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Scotto J, Fraumeni FJ, Lee JAH. Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst. 1976;56:489-491.
2. Cutler S, Young J. Third National Cancer Survey: Incidence Data. Bethesda, MD: National Cancer Institute; 1975.
3. Wilkes SR, Robertson DM, Kurland LT, Campbell RJ. Incidence of uveal malignant melanoma in the resident population of Rochester and Ohnsted County, Minnesota. Am J Ophthalmol. 1979;87:639-641.
4. Singh AD, Topham A. Incidence of uveal melanoma in the United Sates 1973-1997. Ophthalmology. 2003;110:956-961.
5. Kaneko A. Incidence of malignant melanoma of eye in Japan. Jpn J Clin Ophthalmol. 1979;33:941-947.
6. Lemke AJ, Hosten N, Wiegel T, et al. Intraocular metastases: differential diagnosis from uveal melanomas with high-resolution MRI using a surface coil. Eur Radiol. 2001;11:2593-2601.
7. Muller-Miny H, Potter R, Clemens S, Knocke TH. The sensitivity of computed tomography in the detection of malignant melanomas of choroid [in German]. Rofo. 1991;154:425-429.
8. Wada M, Ichiya Y, Katsuragi M, et al. Scintigraphic visualization of human malignant melanoma with N-isopropyl-p-[I-123] iodoamphetamine. Clin Nucl Med. 1985;10:415-417.
9. Liewendahl K, Kairento AL, Pyrhonen S, et al. Localization of melanoma with radiolabelled monoclonal antibody fragments and iodoamphetamine. Eur J Nucl Med. 1986;12:359-362.
10. Cohen MB, Saxton RE, Lake RR, et al. Detection of malignant melanoma with iodine-123 iodoamphetamine. J Nucl Med. 1988;29:1200-1206.
11. Kanegae K, Itoh K, Kato C, Tsukamoto E, Nakada K, Furudate M. Diffuse visualization of bone marrow with I-123 IMP in a malignant melanoma. Clin Nucl Med. 1996;21:734-736.
12. 123I-iodoamphetamine. Nucl Med Commun. 1996;17:153-159.
13. Otsuka N, Sone T, Morita K, Fukunaga M. I-123 iodoamphetamine scintigraphic detection of bone metastases from malignant melanoma. Clin Nucl Med. 1996;21:847-850.
14. Murata K, Suzuki K, Ayakawa Y, Higashi N, Paul Lin PJ. Comparison of I-123 IMP and Ga-67 citrate scintigraphy of malignant melanoma. Clin Nucl Med. 2003;28:704-708.
15. 123I]-iodoamphetamine. J Nucl Med. 1988;29:1448-1450.
16. 123I]-iodoamphetamine single photon emission computed tomography for the diagnosis of uveal malignant melanoma. Am J Ophthalmol. 2001;132:937-939.
17. 123I]-iodoamphetamine single photon emission computed tomography in the follow-up of choroidal melanoma after radiotherapy. Jpn J Ophthalmol. 2004;48:54-58.
18. 123I-IMP SPECT for the diagnosis of malignant uveal melanoma. Int J Clin Oncol. 2004;9:74-78.
19. Lucignani G, Paganelli G, Modorati G, et al. MRI, antibody-guided scintigraphy, and glucose metabolism in uveal melanoma. J Comput Assist Tomogr. 1992;16:77-83.
20. Modorati G, Lucignani G, Landoni C, et al. Glucose metabolism and pathological findings in uveal melanoma: preliminary results. Nucl Med Commun. 1996;17:1052-1056.
21. Spraul CW, Lang GE, Lang GK. Value of positron emission tomography in the diagnosis of malignant ocular tumors. Ophthalmologica. 2001;215:163-168.
22. Gritter LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med. 1993;34:1420-1427.
23. Damian DL, Fulhan MJ, Thomson E, Thompson JF. Positron emission tomography in the detection and management of metastastic melanoma. Melanoma Res. 1996;6:325-329.
24. Wagnaer JD, Schanwecker D, Hutchins G, Coleman JJ 3rd. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol. 1997;64:181-189.
25. 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998;82:1664-1671.
26. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 1998;227:764-769.
27. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol. 1998;16:1770-1776.
28. Eigtved A, Andersson AP, Dahlstrom K, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med. 2000;27:70-75.
29. Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696-703.
30. Cobben DCP, Koopal S, Tiebosch ATMG, et al. New diagnostic techniques in staging in the surgical treatment of cutaneous malignant melanoma. Eur J Surg Oncol. 2002;28:692-700.
31. 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: comparison of ultrasonographic and radiological methods of diagnosis. Nucl Med Commun. 1999;20:255-261.
32. Krug B, Dietlein M, Groth W, et al. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma: diagnostic comparison with conventional imaging methods. Acta Radiol. 2000;41:446-452.
33. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995;36:1625-1632.